Assembly Biosciences (FRA:V7B) Change In Receivables : €0.63 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Change In Receivables?

Assembly Biosciences's change in receivables for the quarter that ended in Mar. 2024 was €0.00 Mil. It means Assembly Biosciences's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Assembly Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was €0.83 Mil. It means Assembly Biosciences's Accounts Receivable declined by €0.83 Mil from Dec. 2022 to Dec. 2023 .

Assembly Biosciences's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.04 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Assembly Biosciences's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.69.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Assembly Biosciences's liquidation value for the three months ended in Mar. 2024 was €23.67 Mil.

Assembly Biosciences Change In Receivables Historical Data

The historical data trend for Assembly Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Change In Receivables Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.85

1.76

0.79

-0.57

0.83

Assembly Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															0.21	0.35	0.32	-0.04	-

Assembly Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.63 Mil.

Assembly Biosciences (FRA:V7B) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Assembly Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.04	/	5.322	*	91
=	0.69

2. In Ben Graham's calculation of liquidation value, Assembly Biosciences's accounts receivable are only considered to be worth 75% of book value:

Assembly Biosciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	103.938	-	80.299	+	0.75 * 0.04	+	0.5 * 0
=	23.67

Assembly Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences (FRA:V7B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ASMB:USA

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines